|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.12 USD | +1.49% |
|
-10.00% | -13.01% |
| 05:28pm | Regenxbio's muscle disorder therapy meets main goal in late-stage study | RE |
| 12/05 | Trump says US FDA Commissioner Makary is out | RE |
Main competitors
| Capi.($) | Investor | ESG MSCI | Fundamentals | Financial revisions | Global Valuation | Visibility | Consensus | ||
|---|---|---|---|---|---|---|---|---|---|
 | 198.91Cr | B | |||||||
| 259.81Cr | - | BB | - | - | ||||
| 34Cr | - | - | - | - | - | - | - | |
| 6.72Cr | - | - | - | - | - | - | - | |
| Average | 124.9Cr | BB | |||||||
| Weighted average by Cap. | BB |
- Stock Market
- Equities
- SRPT Stock
- Sector Sarepta Therapeutics, Inc.
- Sector ratings
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition